Botulinum Toxin Treatment on Migraine Patients; Its Effect on Disability, Severity of Migraine and Depression
Abstract
Objective: Migraine patients have a high risk of developing anxiety and depression, and the relationship between chronic migraine (CM) and depression is believed to be bidirectional.This study aims to evaluate the effects of Botulinum Neurotoxin A (BoNT/A) treatment on migraine-related disability, pain severity, and depression in patients with CM. Materials and Methods:This study included 24 patients aged between 19 and 55 years who were diagnosed with CM and treated with BoNT/A injections every 12 weeks for six months.Data were collected on demographic characteristics, as well as disability severity, pain severity, and depression levels before and after treatment.Results: A statistically significant improvement was observed in VAS (Visual Analog Scale), MIDAS (Migraine Disability Assessment Scale), and BDS (Beck Depression Scale) scores after BoNT/A treatment (p<0.001).The mean changes in scores were as follows: a 4±1-point reduction in VAS, a 61±23-point reduction in MIDAS, and a 16±9-point reduction in BDS.Patients reported experiencing initial treatment benefits within 12±3 days, with an average duration of effect lasting 93±38 days.Conclusion: BoNT/A treatment appears to play a significant role in modulating pain perception and emotional responses, particularly in patients with depression and those resistant to conventional migraine treatments.The findings suggest that BoNT/A may be an effective treatment option for reducing migraine-related disability, pain severity,…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.